Amendments to the Claims:

Listing of the Claims:

Claim 1 (canceled)

Claim 2 (original): A method of treating a warm-blooded animal having hyperparathyroidism comprising administering a therapeutically effective amount of an epothilone derivative of formula I



(I)

wherein A represents O or NR_N, wherein R_N is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,
or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof.

Claim 3 (original): The method according to claim 2 wherein the warm-blooded animal is a human.

Claim 4 (original): The method according to claim 2 in which method an epothilone derivative of formula I wherein A represents O, R is methyl and Z is O or a pharmaceutically acceptable salt thereof is administered to a warm-blooded animal in need thereof.

Claim 5 (original): The method according to claim 4 comprising administering said epothilone derivative weekly in a dose that is between about 0.1 to 6 mg/m2 for three weeks after an interval of one to six weeks after the preceding treatment.

Claim 6 (currently amended): The method according to ~~any one of claims 2 to 5~~ claim 2 wherein the hyperparathyroidism disease is adenoma, hyperplasia or carcinoma.

Claim 7 (original): The method according to claim 6 wherein the disease is parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma.

Claim 8 (currently amended): The method according to ~~any one of claims 2 to 5~~ claim 2 wherein the parathyroid cancer disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 9 (currently amended): The method according to ~~any one of claims 2 to 5~~ claim 2 wherein the hyperparathyroidism disease is primary or secondary hyperparathyroidism.

Claim 10 (original): A method for the treatment of hypercalcemia resulting from parathyroid adenoma, parathyroid hyperplasia or parathyroid carcinoma comprising administering a therapeutically effective amount of an epothilone derivative of formula I



(I)

wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond,
or a pharmaceutically acceptable salt thereof to a warm-blooded animal in need thereof.

Claim 11 (original): The method according to claim 10 wherein the warm-blooded animal is a human.

Claim 12 (original): The method according to claim 10 in which method an epothilone derivative of formula I wherein A represents O, R is methyl and Z is O or a pharmaceutically acceptable salt thereof is administered to a warm-blooded animal in need thereof.

Claim 13 (original): The method according to claim 12 comprising administering said epothilone derivative weekly in a dose that is between about 0.1 to 6 mg/m2 for three weeks after an interval of one to six weeks after the preceding treatment.

Claim 14 (currently amended): The method according to ~~to any one of claims 10 to 13~~ claim 10 wherein the disease is recurrent or persistent parathyroid adenoma, recurrent or persistent parathyroid hyperplasia or recurrent or persistent parathyroid carcinoma.

Claim 15 (original): A pharmaceutical composition comprising a quantity of compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, which is therapeutically effective against hyperparathyroidism.

Claim 16 (original): A commercial package comprising a compound of formula I



wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R' is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino or methylthio, and Z is O or a bond, or a pharmaceutically acceptable salt thereof, together with instructions for use thereof in the treatment of hyperparathyroidism.